GNRH1 and Dysmenorrhea: In a recent phase III randomized and double-blind study, researchers found that a daily dose of 200 mg of linzagolix, a GnRH antagonist, paired with add-back therapy, significantly reduced both dysmenorrhea and non-menstrual pelvic pain after three months.